Has the incidence of end-stage renal disease in the USA and other countries stabilized?

Eggers, Paul W.

doi:10.1097/mnh.0b013e3283454319

Cited by 111 publications

(102 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Diabetic nephropathy (DN) is a common complication of diabetes and its earliest clinical sign is a slight elevation of urinary albumin excretion microalbuminuria (MA). Such leakage was believed to progress inexorably to gross proteinuria, which destroyed nephrons and led to end stage renal disease (ESRD).…”

Section: Introductionmentioning

confidence: 99%

Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients

Fouad¹,

Fathy²,

Zidan³

2016

Jornal Brasileiro De Nefrologia

View full text Add to dashboard Cite

Ácido úrico sérico e sua associação com hipertensão, nefropatia precoce e doença renal crônica em pacientes diabéticos tipo 2 Introdução: A detecção precoce da nefropatia diabética (ND) é importante. O áci-do úrico sérico (AUS) tem um papel ainda desconhecido no desenvolvimento de ND. Objetivo: Estudar a relação entre AUS e hipertensão, nefropatia precoce e progressão da doença renal crônica (DRC) no diabetes mellitus tipo 2 (DM2). Métodos: O estudo contou com 986 participantes, de acordo com a presença e a duração do diabetes, os pacientes foram classificados em três grupos. O Grupo I incluiu 250 participantes saudá-veis. O Grupo II incluiu 352 pacientes com início de diabetes < 5 anos. O Grupo III incluiu 384 pacientes com o aparecimento de diabetes > 5 anos. Todos os participantes foram submetidos a exame clínico completo, medidas antropométricas, exames laboratoriais -incluindo hemoglobina glicosilada (HbA1C), bem como a razão entre triglicé-rides e lipoproteína de alta densidade (TG/ HDL-C), AUS, razão creatinina/albumina (RCA) urinária, e taxa estimada de filtração glomerular (eTFG). Resultados: A razão AUS, PA, HbA1c, TG/HDL-C e RCA foi significativamente maior no grupo III do que no grupo I, II e em II do que I. A eTFG foi significativamente menor no grupo III do que nos grupos I, II e no II do que no I (p < 0,001). Idade, IMC, PA, HbA1c, razão TG/ HDL-C, RCA, foram positivamente correlacionados com AUS, enquanto que a TFG esteve negativamente correlacionada. O AUS a níveis > 6,1 mg/dl, > 6,2 mg/dl e > 6,5 mg/dl apresentou maior sensibilidade e especificidade para identificar hipertensão, nefropatia precoce e declínio da eTFG, respectivamente. Conclusão: Mesmo elevados níveis de AUS, foi associado ao risco de hipertensão, nefropatia precoce e declínio da eTFG. Além disso, o nível de AUS pode identificar o iní-cio da hipertensão, nefropatia precoce e progressão da DRC em DM2. ResumoPalavras-chave: ácido úrico; diabetes mellitus tipo 2; hipertensão; nefropatias diabéticas. Introduction:Early detection diabetic nephropathy (DN) is important. Whether serum uric acid (SUA) has a role in the development of DN is not known. Objective: To study the relationship between SUA and hypertension, early nephropathy and progression of chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM). Methods: The total number of the study was 986 participants, according to presence and duration of diabetes were classified into three groups. Group I; including 250 healthy participants. Group II; including 352 with onset of diabetes < 5 years. Group III; including 384, with the onset of diabetes > 5 years. All participants were submitted to complete clinical examination, anthropometric measurements, laboratory investigations, including glycosylated hemoglobin (HbA1C), as well triglycerides to high-density lipoprotein ratios (TG/HDL-C), SUA, urinary albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). Results: SUA, BP, HbA1c, TG/HDL-C ratio, and ACR levels were significantly higher in group III tha...

show abstract

Section: Introductionmentioning

confidence: 99%

Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients

Fouad¹,

Fathy²,

Zidan³

2016

Jornal Brasileiro De Nefrologia

View full text Add to dashboard Cite

show abstract

“…The number of patients with end-stage chronic kidney disease (CKD) requiring renal replacement therapy has increased progressively worldwide [1] . Permanent vascular access (VA) is the life-line for the majority of these patients when hemodialysis (HD) is the treatment of choice.…”

Section: Introductionmentioning

confidence: 99%

Vascular access today

Pantelias

Grapsa²

2012

WJN

View full text Add to dashboard Cite

The number of patients with chronic kidney disease requiring renal replacement therapy has increased worldwide. The most common replacement therapy is hemodialysis (HD). Vascular access (VA) has a key role for successful treatment. Despite the advances that have taken place in the field of the HD procedure, few things have changed with regards to VA in recent years. Arteriovenous fistula (AVF), polytetrafluoroethylene graft and the cuffed double lumen silicone catheter are the most common used for VA. In the long term, a number of complications may present and more than one VA is needed during the HD life. The most common complications for all of VA types are thrombosis, bleeding and infection, the most common cause of morbidity in these patients. It has been estimated that VA dysfunction is responsible for 20% of all hospitalizations. The annual cost of placing and looking after dialysis VA in the United States exceeds 1 billion dollars per year. A good functional access is also vital in order to deliver adequate HD therapy. It seems that the native AVF that Brescia and Cimino described in 1966 still remains the first choice for VA. The native forearm AVFs have the longest survival and require the fewest interventions. For this reason, the forearm AVF is the first choice, followed by the upper-arm AVF, the arteriovenous graft and the cuffed central venous catheter is the final choice. In conclusion, VA remains the most important issue for patients on HD and despite the technical improvements, a number of problems and complications have to be resolved.

show abstract

“…По современным оценкам ВОЗ, распростра-ненность хронической болезни почек (ХБП) составляет 5-7% среди взрослого населения в экономически развитых странах [10][11][12], более 2 млн человек проводится терапия, замещающая функцию почек, однако это менее 10% от числа нуждающихся [13]. По данным многочисленных исследований, наличие в анам-незе ХБП значительно повышает риск развития ССЗ, особенно в сочетании с артериальной гипертонией (АГ) и СД-2 [14,15].…”

Section: терапевтический архив 1 2015unclassified

Renal dysfunction in patients with myocardial infarction concurrent with type 2 diabetes mellitus

Евсеева¹,

Каретникова²,

Барбараш³

2015

Ter. arkh.

View full text Add to dashboard Cite

Has the incidence of end-stage renal disease in the USA and other countries stabilized?

Abstract: It is likely that the absolute numbers of incident ESRD patients will continue to increase in westernized countries due to the aging of those populations. In developing countries, ESRD incidence will increase to the extent that economic development allows.

Cited by 111 publications

References 21 publications

Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients

Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients

Vascular access today

Renal dysfunction in patients with myocardial infarction concurrent with type 2 diabetes mellitus

Contact Info

Product

Resources

About